Amgen's cholesterol drug shows positive effect in cardiovascular outcomes study – Pharmaceutical Business Review

20. March 2017 Health, HIPAA 0
U.S. News & World Report Amgen’s cholesterol drug shows positive effect in cardiovascular outcomes studyPharmaceutical Business ReviewAmgen’s cholesterol drug Repatha (evolocumab) has showed positive effect in a 27,564-patient cardiovascular outcomes study. The trial demonstrated that Repatha has maximum reduced low-density lipoprotein cholesterol (LDL-C) levels, helping to …AMGN On Watch, GALE Reports Positive Data, EBS Secures BARDA ...